Inactive Instrument

OHR Pharmaceutical Inc Nasdaq

Equities

US67778H3093

Biotechnology & Medical Research

Ohr Pharmaceutical Regains Compliance with NASDAQ Listing Requirements

February 21, 2019 at 10:46 am EST

NEW YORK, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) today announced that it received notice from The Nasdaq Stock Market LLC indicating that the Company has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) (the "Bid Price Rule") for continued listing on The NASDAQ Capital Market. Accordingly, the Company has regained compliance with the Bid Price Rule and NASDAQ considers the matter closed.

Ohr Pharmaceutical Contact:
Investor Relations
OP: 212-682-8452
ir@ohrpharmaceutical.com

Latest news about OHR Pharmaceutical Inc

Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading	Mar. 26	MT
US Futures Trend Higher Ahead of Durable Goods, House Prices, Consumer Confidence Readings	Mar. 26	MT
Top Premarket Decliners	Mar. 26	MT
North American Morning Briefing : Tech in Focus on -2-	Mar. 25	DJ
North American Morning Briefing : Investors -2-	Mar. 18	DJ
North American Morning Briefing : Stock Futures -2-	Mar. 11	DJ
North American Morning Briefing : Traders Await -2-	Feb. 26	DJ
NeuBase Therapeutics, Inc. Announces CEO Changes	Jan. 17	CI
North American Morning Briefing : S&P 500 Eyes Record High as Rate Cut Hopes Underpin Sentiment	Dec. 19	DJ
NeuBase Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Neubase Therapeutics, Inc. Announces Franklyn G. Prendergast Board of Directors Passed Away	23-10-20	CI
Top Premarket Decliners	23-09-07	MT
Top Midday Gainers	23-09-06	MT
NEUBASE THERAPEUTICS SHARES UP 40% AFTER SYMETRYX CORPORATION AC…	23-09-06	RE
Top Premarket Gainers	23-09-06	MT
North American Morning Briefing : Stock Futures -2-	23-08-16	DJ
NeuBase Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
NeuBase Therapeutics to Explore Strategic Alternatives	23-08-03	CI
NeuBase Therapeutics, Inc. announced that it has received $3.512751 million in funding	23-06-29	CI
NeuBase Therapeutics, Inc. Presents Non-Human Primate Data Illustrating Stealth Editors Are Non-Immunogenic, Opening the Door to Redosing	23-06-29	CI
NeuBase Therapeutics Launches $5 Million Registered Direct Offering, Concurrent Private Placement	23-06-28	MT
NeuBase Therapeutics, Inc. announced that it expects to receive $3.512751 million in funding	23-06-27	CI
NeuBase Therapeutics, Inc.(NasdaqCM:NBSE) dropped from Russell 3000E Value Index	23-06-23	CI
NeuBase Therapeutics, Inc.(NasdaqCM:NBSE) dropped from Russell Microcap Index	23-06-23	CI
NeuBase Therapeutics, Inc.(NasdaqCM:NBSE) dropped from Russell Microcap Value Index	23-06-23	CI

Chart OHR Pharmaceutical Inc

Duration

Period

More charts

Company Profile

NeuBase Therapeutics, Inc. is a preclinical-stage biotechnology company. It is developing a modular peptide-nucleic acid (PNA) antisense oligo (PATrOL) platform to address genetic diseases, with a single, cohesive approach. The Companyâs programs are NT-0100 in HD, NT-0200 in myotonic dystrophy type 1 (DM1) and NT-0300 in KRAS-driven cancers. The NT-0100 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the HD DNA or RNA. The NT-0200 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease RNA. The NT-0300 program is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene. It uses its platform to address diseases which have a genetic source, with an initial focus on gene silencing in DM1, Huntingtonâs disease (HD), and oncology and in gene editing applications. It also focused on identifying and evaluating multiple indications for potential development.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+4.09%	43.43B
LONZA GROUP AG	+47.81%	41.69B
MODERNA, INC.	+9.45%	41.31B
CELLTRION, INC.	-10.92%	27.14B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.28B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.47B
MEDPACE HOLDINGS, INC.	+29.70%	12.59B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.33B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.03B

Other Biotechnology & Medical Research